Sulconazole NitrateCAS# 61318-91-0 |
- Hyoscyamine
Catalog No.:BCN1946
CAS No.:101-31-5
- Neostigmine Bromide
Catalog No.:BCC4563
CAS No.:114-80-7
- Tropicamide
Catalog No.:BCC4574
CAS No.:1508-75-4
- Otilonium Bromide
Catalog No.:BCC4573
CAS No.:26095-59-0
- Flavoxate hydrochloride
Catalog No.:BCC5208
CAS No.:3717-88-2
- Homatropine Methylbromide
Catalog No.:BCC4571
CAS No.:80-49-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 61318-91-0 | SDF | Download SDF |
| PubChem ID | 65495 | Appearance | Powder |
| Formula | C18H16Cl3N3O3S | M.Wt | 460.76 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | 1-[2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid | ||
| SMILES | C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl.[N+](=O)(O)[O-] | ||
| Standard InChIKey | CRKGMGQUHDNAPB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H15Cl3N2S.HNO3/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21;2-1(3)4/h1-9,12,18H,10-11H2;(H,2,3,4) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Sulconazole Nitrate Dilution Calculator
Sulconazole Nitrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1703 mL | 10.8516 mL | 21.7033 mL | 43.4065 mL | 54.2582 mL |
| 5 mM | 0.4341 mL | 2.1703 mL | 4.3407 mL | 8.6813 mL | 10.8516 mL |
| 10 mM | 0.217 mL | 1.0852 mL | 2.1703 mL | 4.3407 mL | 5.4258 mL |
| 50 mM | 0.0434 mL | 0.217 mL | 0.4341 mL | 0.8681 mL | 1.0852 mL |
| 100 mM | 0.0217 mL | 0.1085 mL | 0.217 mL | 0.4341 mL | 0.5426 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Sulconazole Nitrate is an imidazole derivative with broad-spectrum antifungal activity.
- Boc-D-Arg(Tos)-OH
Catalog No.:BCC3070
CAS No.:61315-61-5
- Isoacteoside
Catalog No.:BCN4137
CAS No.:61303-13-7
- Schisandrin C
Catalog No.:BCN1198
CAS No.:61301-33-5
- 2-Aminoacetophenone
Catalog No.:BCC8546
CAS No.:613-89-8
- 2-(Phenylmethoxy)-naphthalene
Catalog No.:BCC8485
CAS No.:613-62-7
- AKT inhibitor VIII
Catalog No.:BCC1334
CAS No.:612847-09-3
- Schizandrin A
Catalog No.:BCN1021
CAS No.:61281-38-7
- Schizandrin B
Catalog No.:BCN1022
CAS No.:61281-37-6
- Boc-D-Phe(4-NO2)-OH
Catalog No.:BCC3276
CAS No.:61280-75-9
- Acteoside
Catalog No.:BCN4136
CAS No.:61276-17-3
- Vitexilactone
Catalog No.:BCN4135
CAS No.:61263-49-8
- Cannabispiran
Catalog No.:BCN4134
CAS No.:61262-81-5
- Neoschaftoside
Catalog No.:BCN3053
CAS No.:61328-41-4
- Amoxicillin trihydrate
Catalog No.:BCC5168
CAS No.:61336-70-7
- Boc-D-Gln-OH
Catalog No.:BCC2607
CAS No.:61348-28-5
- Boc-D-Glu-OH
Catalog No.:BCC2606
CAS No.:61348-28-6
- VU 0364770
Catalog No.:BCC4597
CAS No.:61350-00-3
- TNP-ATP triethylammonium salt
Catalog No.:BCC7373
CAS No.:61368-63-6
- erythro-Guaiacylglycerol-beta-O-4'-dehydrodisinapyl ether
Catalog No.:BCN7024
CAS No.:613684-55-2
- Griffonilide
Catalog No.:BCN1271
CAS No.:61371-55-9
- Rifapentine
Catalog No.:BCC4937
CAS No.:61379-65-5
- Trigonelline hydrochloride
Catalog No.:BCN1050
CAS No.:6138-41-6
- Naginata ketone
Catalog No.:BCN7801
CAS No.:6138-88-1
- 3-Amino-3-phenylpropionic acid
Catalog No.:BCC8609
CAS No.:614-19-7
Sulconazole nitrate 1% cream in the treatment of chronic moccasin-type tinea pedis caused by Trichophyton rubrum.[Pubmed:2681281]
J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):686-9.
Sulconazole Nitrate 1% cream applied twice daily was compared with its vehicle in the treatment of 229 patients with chronic moccasin-type tinea pedis confirmed by positive results of a potassium hydroxide preparation. At admission in this randomized, double-blind, parallel multicenter trial, 131 patients had positive dermatophyte cultures; Trichophyton rubrum was identified in 121 (92%). After 4 weeks of treatment, patients were examined and, if necessary, were treated for an additional 2 weeks. Sulconazole cream was significantly more effective than the vehicle in the treatment of chronic T. rubrum tinea pedis; 57% of patients were cured by sulconazole, compared with 13% cured with the vehicle. Relapse rates, assessed 2 weeks after the end of treatment, were significantly lower in patients treated with sulconazole than in those receiving vehicle (27% vs 71%). The 103 patients with moccasin-type tinea pedis whose cultures were not positive for T. rubrum achieved similar results.
Sulconazole nitrate cream 1 percent for treating tinea cruris and corporis.[Pubmed:2805811]
Cutis. 1989 Oct;44(4):344-7.
Sulconazole Nitrate 1 percent cream, a new imidazole derivative, was tested in 117 Colombian Army soldiers with tinea cruris/corporis under hot, humid conditions. The results of two clinical trials demonstrate that sulconazole applied once daily was as effective as clotrimazole applied twice daily. After three weeks of therapy 100 percent of the patients treated either once or twice daily with sulconazole showed negative findings on potassium hydroxide preparations and cultures from lesions. Although sulconazole was well tolerated and caused no adverse reactions, four of twenty-seven clotrimazole-treated patients showed reactions consisting of erosive primary irritation. Sulconazole Nitrate 1 percent cream appears to be highly effective in the treatment of tinea cruris/corporis when applied once or twice daily and may be very useful in hot and humid conditions where contact irritation reactions occur more often.
Pharmacokinetics of cutaneous Sulconazole nitrate in the hairless rat: absorption, excretion, tissue concentrations.[Pubmed:8243497]
Eur J Drug Metab Pharmacokinet. 1993 Apr-Jun;18(2):149-54.
After cutaneous application of radioactive solutions of Sulconazole Nitrate in the hairless rat, the total absorption of the substance by the skin, estimated from the sum of the cumulative urinary and fecal excretions over 96 h, was 2.4% of the dose administered. The elimination reached a maximum between 6 and 24 h and was virtually complete after 96 h. The excretion was almost equally distributed between the urine and the feces, which corresponds to an intense elimination via the biliary tract. The quantities present in the stratum corneum, epidermis and dermis at the end of the period of contact constituted another estimation of the total absorption of the substance which confirmed the previous estimation (3.6% of the dose). The measurement of the concentrations of Sulconazole and its metabolites in the various layers of the skin revealed a high affinity of the substance for the stratum corneum, where it remained present in large quantities for more than 48 h. This affinity is due to the very intense lipophilia of the molecule. The concentrations in the other tissues were inversely proportional to the distance from the surface of the skin and were virtually nil in the circulating blood. These results suggest the absence of risk of systemic effects after cutaneous administration of Sulconazole and support the recommended therapeutic protocol in man (one administration per day).
